Literature DB >> 25865077

First experience of liver transplantation with type 2 donation after cardiac death in France.

Eric Savier1, Federica Dondero, Eric Vibert, Daniel Eyraud, Hélène Brisson, Bruno Riou, Fabienne Fieux, Salima Naili-Kortaia, Denis Castaing, Jean-Jacques Rouby, Olivier Langeron, Safi Dokmak, Laurent Hannoun, Jean-Christophe Vaillant.   

Abstract

Organ donation after unexpected cardiac death [type 2 donation after cardiac death (DCD)] is currently authorized in France and has been since 2006. Following the Spanish experience, a national protocol was established to perform liver transplantation (LT) with type 2 DCD donors. After the declaration of death, abdominal normothermic oxygenated recirculation was used to perfuse and oxygenate the abdominal organs until harvesting and cold storage. Such grafts were proposed to consenting patients < 65 years old with liver cancer and without any hepatic insufficiency. Between 2010 and 2013, 13 LTs were performed in 3 French centers. Six patients had a rapid and uneventful postoperative recovery. However, primary nonfunction occurred in 3 patients, with each requiring urgent retransplantation, and 4 early allograft dysfunctions were observed. One patient developed a nonanastomotic biliary stricture after 3 months, whereas 8 patients showed no sign of ischemic cholangiopathy at their 1-year follow-up. In comparison with a control group of patients receiving grafts from brain-dead donors (n = 41), donor age and cold ischemia time were significantly lower in the type 2 DCD group. Time spent on the national organ wait list tended to be shorter in the type 2 DCD group: 7.5 months [interquartile range (IQR), 4.0-11.0 months] versus 12.0 months (IQR, 6.8-16.7 months; P = 0.08. The 1-year patient survival rates were similar (85% in the type 2 DCD group versus 93% in the control group), but the 1-year graft survival rate was significantly lower in the type 2 DCD group (69% versus 93%; P = 0.03). In conclusion, to treat borderline hepatocellular carcinoma, LT with type 2 DCD donors is possible as long as strict donor selection is observed.
© 2015 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25865077     DOI: 10.1002/lt.24107

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  5 in total

1.  The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation.

Authors:  Karen L Thomsen; Francis P Robertson; Peter Holland-Fischer; Brian R Davidson; Rajeshwar P Mookerjee; Holger J Møller; Rajiv Jalan; Henning Grønbæk
Journal:  J Clin Exp Hepatol       Date:  2018-10-05

2.  Donation after circulatory death liver transplantation: consensus statements from the Spanish Liver Transplantation Society.

Authors:  Amelia J Hessheimer; Mikel Gastaca; Eduardo Miñambres; Jordi Colmenero; Constantino Fondevila
Journal:  Transpl Int       Date:  2020-05-15       Impact factor: 3.782

3.  Evaluation of Liver Quality after Circulatory Death Versus Brain Death: A Comparative Preclinical Pig Model Study.

Authors:  Jérôme Danion; Raphael Thuillier; Géraldine Allain; Patrick Bruneval; Jacques Tomasi; Michel Pinsard; Thierry Hauet; Thomas Kerforne
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

4.  Liver transplantation for hepatocellular carcinoma using grafts from uncontrolled circulatory death donation.

Authors:  Anisa Nutu; Iago Justo; Alberto Marcacuzco; Óscar Caso; Alejandro Manrique; Jorge Calvo; Álvaro García-Sesma; María García-Conde; María Santos Gallego; Carlos Jiménez-Romero
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

5.  Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month.

Authors:  Daniel Eyraud; Ludovic Suner; Axelle Dupont; Christilla Bachelot-Loza; David M Smadja; Dominique Helley; Sébastien Bertil; Ovidiu Gostian; Jean Szymezak; Yann Loncar; Louis Puybasset; Pascal Lebray; Corinne Vezinet; Jean-Christophe Vaillant; Benjamin Granger; Pascale Gaussem
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.